Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca shareholders overwhelmingly approved all resolutions at the 9 April 2026 Annual General Meeting, including reappointment of KPMG as auditor, confirmation of 2025 interim dividends and wide-ranging authorities on share allotment, buybacks and reduced notice periods. The board was largely re-elected with strong support, though director Marcus Wallenberg drew a notable 16% vote against, while long-serving non-executive Nazneen Rahman retired, underscoring broad but not uniform investor backing for the company’s governance and capital-management framework, with 77% of the issued share capital voting.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca PLC is a global, science-led biopharmaceutical company headquartered in Cambridge, UK, specialising in the discovery, development and commercialisation of prescription medicines. Its core therapeutic areas are Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with products sold in more than 125 countries.
Average Trading Volume: 2,757,382
Technical Sentiment Signal: Buy
Current Market Cap: £236B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.